Changzhou Pharmaceutical Factory, based in China, is a pharmaceutical company that stands out with its certifications from FDA and EDQM.
One of their notable products is ABROCITINIB, with a corresponding US DMF Number 39291.
Remarkably, this DMF maintains an Active status since its submission on December 27, 2023, highlighting commitment to regulatory compliance.
Their GDUFA DMF Review was successfully complete, with a review date of May 06, 2025, and payment made on March 27, 2025, indicating their dedication to facilitating drug approvals, Categorized as Type II